Oncolytics Biotech to Present at the Canaccord Genuity 38th Annual Growth Conference


Oncolytics BiotechA Inc. , currently developing REOLYSINA , an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference. The presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 9:30 am ET, on Wednesday, August 8, 2018 in the Hong Kong Room at the Intercontinental Hotel.



from Biotech News